ArticlePloS one2026
Updated data on the epidemiology of Inflammatory Bowel Disease (IBD) in Lebanon.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stigma management, social support, and quality of life among adults with Crohn's disease and ulcerative colitis in Saudi Arabia: A cross-sectional study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Presentation and Clinical Outcomes of Inflammatory Bowel Disease in Children and Adolescents at a Tertiary Care Center in Lebanon.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of the study was to review available data on IBD in Lebanon based on histopathological reports and endoscopic data to identify the number of newly diagnosed cases per year, age, gender, and disease phenotype, and subsequently update the incidence and prevalence of the disease.
methodsA review of all histopathological reports of newly diagnosed IBD patients over a 20-year period was conducted, along with a review of available clinical and endoscopic information at the National Institute of Pathology. The clinical data analysed included the type of IBD, age, gender, number of cases diagnosed per year, location of each IBD type and disease progression over time. The Montreal classification for age and phenotype was applied to both diseases.
resultsOver a 20-year period (from January 2000 to December 2020), 2,869 IBD patients (1,365 with Crohn's disease (CD) and 1,504 with ulcerative colitis (UC) were included. Our sample represents 20% of the Lebanese population with IBD. No cases of unclassified IBD were identified since all patients were followed up throughout the years. The male-to-female ratio was 1.15 for UC patients and 1.3 for CD patients. The average age was 41 years for UC and 36.4 years for CD. Ileal involvement and left-sided colonic involvement were the most frequently noted in CD and UC, respectively. A progressive increase in diagnosed cases of CD and UC was observed over this 20-year period. The annual incidence rose from 4.9 to 11 per 100,000, with a cumulative incidence of 6.53 per 100,000 and a prevalence of 130.56 per 100,000. The highest incidence occurred between ages 21-30. Incidence trends were independently predicted by age group and calendar period, with markedly higher rates among individuals aged 20-39 and 40-59 years with a significant increase in the 2015-2020 period, whereas sex and disease type showed no significant associations.
conclusionEpidemiological data demonstrated a progressive increase in the incidence of IBD over this 20-year period, with a slight male predominance. Ileal involvement is predominant in CD, whereas involvement extending beyond the splenic flexure is present in more than half of UC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.